EHMTI-0120. Are the IHS’ recommendations for evaluation and registration of adverse events in drug trials in migraine being followed ? by P Tfelt-Hansen & J Kauffmann
MEETING ABSTRACT Open Access
EHMTI-0120. Are the IHS’ recommendations for
evaluation and registration of adverse events in
drug trials in migraine being followed ?
P Tfelt-Hansen1*, J Kauffmann2
From 4th European Headache and Migraine Trust International Congress: EHMTIC 2014
Copenhagen, Denmark. 18-21 September 2014
Introduction
In 2008 the International Headache Society (IHS) pub-
lished guidelines on “evaluation and registration of adverse
events in clinical drug trials in migraine (Cephalalgia 2008;
28: 683-688). In this study we evaluated whether these
guidelines on adverse events (AEs) subsequently were
adhered to by reviewing , randomized, controlled trials
(RCTs) on migraine drug treatment published in the three
leading headache journals for the last 4 years.
Methods
We reviewed all double-blind RCTs on acute and pre-
ventive migraine drugs appearing in 2010, 2011, 2012,
and 2013 in Headache, Journal of Headache and Pain,
and Cephalalgia.
We noted for each RTC the presentations of 5 para-
meters: number of patients with any AEs, any serious
AEs, patients withdrawn because of AEs, intensity of
AEs, see results.
Results
At total of 23 RCTs , 17 acute treatment RCTs and 6
preventive RCTs, were reviewed.
Patients with any AEs were reported in 16 of 23
RCTs; any serious AEs were reported in 8 of 23 RCTs;
patients withdrawn because of AEs were reported in 5
of 23 RCTs; and intensity of AES was mentioned in 8 of
23 RCTs (in most cases e.g. most AEs were mild and
moderate).
Discussion
It is noteworthy that even such an obvious major para-
meter for tolerability, patients with any AES, was only
reported in 70% (95% CI: 51 – 89%) of the reviewed
RCTs. In addition, intensity of AEs is only very briefly
reported.
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